Dimensional Fund Advisors’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

Dimensional Fund Advisors’s Portfolio CNCE Stock Details CNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$4.44M	Sell	662,100 -154,073	-19%	-$934K	﹤0.01%	2470
2022 Q2	$3.44M	Buy	816,173 +37,577	+5%	+$149K	﹤0.01%	2570
2022 Q1	$2.62M	Buy	778,596 +63,860	+9%	+$202K	﹤0.01%	2753
2021 Q4	$2.25M	Sell	714,736 -28,637	-4%	-$95.3K	﹤0.01%	2816
2021 Q3	$2.43M	Sell	743,373 -137,492	-16%	-$482K	﹤0.01%	2800
2021 Q2	$3.72M	Sell	880,865 -126,630	-13%	-$536K	﹤0.01%	2688
2021 Q1	$5.03M	Sell	1,007,495 -71,675	-7%	-$579K	﹤0.01%	2583
2020 Q4	$13.6M	Sell	1,079,170 -15,405	-1%	-$176K	﹤0.01%	2157
2020 Q3	$10.7M	Sell	1,094,575 -24,615	-2%	-$243K	﹤0.01%	2159
2020 Q2	$11.1M	Sell	1,119,190 -5,630	-0.5%	-$54K	﹤0.01%	2152
2020 Q1	$9.94M	Sell	1,124,820 -84,181	-7%	-$830K	0.01%	2122
2019 Q4	$11.2M	Buy	1,209,001 +17,893	+2%	+$127K	﹤0.01%	2308
2019 Q3	$7M	Buy	1,191,108 +8,922	+0.8%	+$94.7K	﹤0.01%	2486
2019 Q2	$14.2M	Buy	1,182,186 +42,753	+4%	+$460K	0.01%	2233
2019 Q1	$13.8M	Buy	1,139,433 +10,267	+0.9%	+$151K	0.01%	2257
2018 Q4	$14.2M	Buy	1,129,166 +59,671	+6%	+$824K	0.01%	2176
2018 Q3	$15.9M	Buy	1,069,495 +126,053	+13%	+$1.98M	0.01%	2238
2018 Q2	$15.9M	Buy	943,442 +205,796	+28%	+$4M	0.01%	2218
2018 Q1	$16.9M	Buy	737,646 +405,592	+122%	+$9.02M	0.01%	2143
2017 Q4	$8.59M	Buy	332,054 +63,165	+23%	+$1.27M	﹤0.01%	2434
2017 Q3	$3.97M	Sell	268,889 -33,051	-11%	-$480K	﹤0.01%	2673
2017 Q2	$4.21M	Hold	301,940	–	–	﹤0.01%	2647
2017 Q1	$5.15M	Sell	301,940 -7,421	-2%	-$89K	﹤0.01%	2554
2016 Q4	$3.18M	Sell	309,361 -14,363	-4%	-$131K	﹤0.01%	2685
2016 Q3	$3.27M	Sell	323,724 -4,743	-1%	-$51.8K	﹤0.01%	2643
2016 Q2	$3.69M	Buy	328,467 +10,452	+3%	+$133K	﹤0.01%	2601
2016 Q1	$4.34M	Buy	318,015 +93,667	+42%	+$1.35M	﹤0.01%	2541
2015 Q4	$4.26M	Buy	224,348 +179,998	+406%	+$3.91M	﹤0.01%	2583
2015 Q3	$832K	Buy	+44,350	New	+$754K	﹤0.01%	3027

Other funds holding CNCE

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

PHP

Parkman Healthcare Partners Stamford, Connecticut $977M AUM 110.37% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Dimensional Fund Advisors's CNCE Position: Q3 2022 in Review

Dimensional Fund Advisors reduced its Concert Pharmaceuticals, Inc. (CNCE) stake by 19% in Q3 2022, selling an estimated $934K and leaving 662,100 shares worth $4.44M. The position accounts for ﹤0.01% of the portfolio, ranked #2470.

Dimensional Fund Advisors first reported a position in CNCE in Q3 2015 and has held it in 29 quarters since. The position peaked at $16.9M in Q1 2018. 80 funds tracked by Wall St. Rank hold CNCE as of Q3 2022.

Dimensional Fund Advisors held 662,100 shares of Concert Pharmaceuticals, Inc. worth $4.44M as of Q3 2022.
Dimensional Fund Advisors sold 154,073 Concert Pharmaceuticals, Inc. shares in Q3 2022, an estimated $934K.
Concert Pharmaceuticals, Inc. made up ﹤0.01% of Dimensional Fund Advisors's portfolio in Q3 2022, its #2470 holding.
Dimensional Fund Advisors first reported a position in Concert Pharmaceuticals, Inc. in Q3 2015 and has held it in 29 quarters since.
Dimensional Fund Advisors's Concert Pharmaceuticals, Inc. position peaked at $16.9M in Q1 2018.
80 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q3 2022.

Based on Dimensional Fund Advisors's 13F filing for Q3 2022, filed 10 Nov 2022.